Background: The first-line combination of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) plus platinum-based doublet chemotherapy has not been sufficiently evaluated for patients with EGFR-mutant non-small cell lung cancer (NSCLC). This randomized phase II study was designed to select a combination regimen for phase III evaluation.
INTRODUCTION
A growing body of evidence, together with our North East Japan Study Group (NEJ) 002 study, demonstrated the superiority of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) over standard chemotherapy with regards to progression-free survival (PFS) and response for non-small cell lung cancer (NSCLC) with sensitive EGFR mutations [1] [2] [3] [4] [5] [6] .
Furthermore, a supplemental analysis of NEJ002 demonstrated that quality of life was also improved with EGFR-TKI therapy [7] . Thus, first-line EGFR-TKI therapy became a standard first-line treatment for EGFR-mutant NSCLC.
Most previous clinical trials failed to show a benefit for EGFR-TKI plus platinum-based doublet chemotherapy in unselected or clinically selected NSCLC patients [8] [9] [10] [11] [12] . However, in the TRIBUTE (Tarceva Responses in Conjunction with Paclitaxel and Carboplatin) study, median time to progression was improved in a subgroup analysis of EGFR-mutated NSCLC [13] . Likewise, continuous erlotinib in combination with carboplatin and paclitaxel conferred a better response and survival outcomes in an EGFR-mutant population [12] .
Collectively, these results indicate that the first-line combination of EGFR-TKI and platinum-based doublet chemotherapy might improve clinical outcomes for NSCLC harboring EGFR mutations. However, to the best of our knowledge, this concept has not been sufficiently evaluated in the EGFR-mutated setting.
This multi-center randomized phase II trial, NEJ005 and Tokyo Cooperative Oncology Group (TCOG) 0902, was designed to explore the efficacy and safety of gefitinib plus carboplatin/pemetrexed and to select a proper regimen for phase III evaluation in advanced NSCLC harboring active 6 EGFR mutations.
PATIENTS AND METHODS

Patient Eligibility
This study was approved by the ethics review boards at each participating institute and was conducted according the Declaration of Helsinki.
Each patient provided written informed consent prior to enrollment.
The main eligibility criteria were: chemotherapy-naïve; stage IIIB, IV, or 
Study Design
Patients were stratified according to sex and clinical stage of NSCLC (IIIB, IV, or postoperative relapse). Eighty patients were randomly assigned to receive either concurrent or sequential alternating regimen. Details of the study treatment are shown in Supplementary Figure S1 . Patients in the concurrent regimen group received concurrent gefitinib (250 mg daily) and carboplatin (6 × area under the curve [AUC], day 1)/pemetrexed (500 mg/m 2 , day 1) in a 3-week cycle for up to six cycles, followed by concurrent gefitinib and pemetrexed maintenance until disease progression, unacceptable toxicity, or death. Patients in the sequential alternating regimen group initially received 8 weeks of gefitinib and then two cycles of carboplatin/pemetrexed; this sequential treatment was repeated up to three times (carboplatin/pemetrexed was repeated for up to six cycles), followed by alternating gefitinib and pemetrexed maintenance. When patients received four cycles or more of carboplatin/pemetrexed with gefitinib, the induction therapy was considered complete. Dose modification and treatment assessment are described in Supplementary Materials.
Patients were enrolled from January 2010 to April 2012.
Protocol-defined final analysis was planned after a 2-year follow-up period (March 31, 2014).
Statistical Analysis
The primary objective was to select the arm with superior PFS. In subgroup analysis for EGFR-mutated NSCLC in the TRIBUTE study, median time to progression was 12.5 months [13] . The arm with the superior PFS was selected, provided that the related PFS was at least 12 months and resulted in PFS prolongation of 4 or more months with a probability of 90% or higher. The planned sample size was 40 eligible patients per arm. Secondary endpoints included overall survival (OS), objective tumor response, and toxicity profile.
This study was not designed to have adequate power to detect a statistically significant difference in efficacy and safety between the two regimens, thus the p value reported for the difference was to be interpreted as exploratory.
PFS was evaluated for the period from the date of randomization to the date on which progression was first confirmed by assessment by the investigator.
OS was evaluated for the period from the date of randomization to the date of death from any cause. For patients without any events, data were censored on the last date with non-event status. The probability of PFS or OS was estimated using the Kaplan-Meier method, and survival curves were compared using a log-rank test. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a Cox proportional-hazards analysis with gender and clinical stage as covariates. The response rate and rate of toxic effects were compared between the two groups with Fisher's exact test. Statistical analysis was carried out using the SAS version 9.1.3 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Patient Characteristics
From January 2010 to April 2012, 80 patients were randomly assigned: 41 to the concurrent regimen and 39 to the sequential alternating regimen ( Figure 1 ). All the patients received at least one dose of the study treatment. The median follow-up period was 30.7 months (range, 4.9 to 50.1 months). The demographics and disease characteristics of the patients were well-balanced between the treatment groups ( Table 1) . One patient with PS 2 was enrolled because the PS had changed from 1 to 2 during the screening process. Of note, all patients had adenocarcinoma, and the majority had stage IV disease. In addition to the Del19 and L858R, two patients exhibited minor EGFR mutations in the sequential alternating regimen group (one G719A, one coexistence of G719A and Del19). Treatment delivery is described in Supplementary Material.
Efficacy
Data for patients without progression (eight patients in the concurrent and six patients in the sequential alternating regimen group) or for those who started off-study second-line treatment before confirmation of progression (one patient in the concurrent and two patients in the sequential alternating regimen group) were censored at the time of data cutoff (March 31, 2014). PFS curves were identical between the two groups ( Figure 2A ). Median PFS was 18.3 months (95% CI, 9.7-21.9 months) for patients in the concurrent regimen group and 15.3 months (95% CI, 11.3-17.4 months) for patients in the sequential alternating regimen group (HR 0.71 [95% CI, 0.42-1.20]; p = 0.20).
However, OS time between the groups was significantly different ( Figure   2B ). Although survival data are immature, with 50% of patients censored (25 patients in the concurrent and 15 patients in the sequential alternating group), median OS was 41.9 months (95% CI, 35.1 months-Not reached) in the concurrent regimen group and 30.7 months (95% CI, 23.2-40.5 months) in the sequential alternating regimen group (HR 0.51 [95% CI, 0.26-0.99]; p = 0.042).
The objective response rates in the concurrent and sequential alternating regimen group were 87.8% and 84.6% (p = 0.75, Supplementary   Table S1 ), respectively, whereas the disease control rates were 100% and 92.3% (p = 0.11). As shown in a representative waterfall plot ( Figure 3 ), deep tumor regression in a substantial proportion of the patients was observed with seven patients (four and three patients for the concurrent and sequential alternating regimen, respectively) exhibiting CR response. Treatment post RECIST progression is shown in Supplementary Table S2 . Subset analyses by types of common EGFR mutations are shown in Supplementary Figure S2 and S3.
Safety
The most common grade 3 or 4 hematological adverse events were neutropenia (48.8% vs. 46.2%), anemia (34.1% vs. 12.8%) and thrombocytopenia (41.5% vs. 28.2%) ( Table 2 ). In contrast, adverse non-hematological events were not severe. The most commonly reported grade 3 or 4 adverse events likely related to carboplatin and pemetrexed were vomiting (2.4% vs. 0.0%), appetite loss (7.3% vs. 0.0%), fatigue (2.4% vs. 0.0%), and febrile neutropenia (2.4% vs. 5.1%). The most commonly reported grade 3 or 4 adverse events likely related to gefitinib included diarrhea (9.8% vs. 0.0%), rash (2.4% vs. 0.0%), stomatitis (4.9% vs. 0.0%), paronychia (2.4% vs. 2.6%), and AST/ALT elevation (9.8% vs. 20.5%). We recorded no increase in fatal events; a total of 4 interstitial lung diseases (5% of all patients) occurred (grade 1 and 2 events in the concurrent; and grade 2 and 4 events in the sequential alternating regimen group), but they were reversible and not fatal.
DISCUSSION
To the best of our knowledge, this is the first randomized study to examine the efficacy of first-line combination of EGFR-TKI and chemotherapy in patients with NSCLC harboring EGFR mutations. Although not formally compared, PFS with both regimens was improved when compared to that with gefitinib monotherapy in previous phase III studies (median, 9.2-10.8 months) [2, 3, 14] .
The results of the current selection-design study indicate that the concurrent regimen with superior PFS (median) should be selected for further evaluation. Before this final analysis, we had already initiated the phase III NEJ009 (UMIN000006340) study, which is comparing this combination strategy with standard gefitinib monotherapy in the EGFR-mutated setting, with OS as the primary endpoint. Efficacy, safety, and feasibility in clinical practice by interim monitoring were considered when choosing the concurrent regimen as an experimental arm in the NEJ009 study.
In the NEJ002 study, OS was improved in patients who received both TKI and platinum-based doublet chemotherapy sequentially [15] . In addition, pemetrexed maintenance therapy extended both OS and PFS, and therefore became a standard treatment option for advanced non-squamous NSCLC [16, 17] . These results encouraged us to adopt carboplatin and pemetrexed induction followed by pemetrexed maintenance as a partner for gefitinib in this combinational strategy.
However, it is still controversial whether patients can benefit from the In this study, despite the identical PFS between the groups, better OS was observed in the concurrent regimen group. The reasons for this survival outcome are not readily identifiable. The majority of patients had deep tumor regression, with seven patients having CR ( Figure 3) ; however, some patients exhibited initial progression in the sequential alternating regimen group. Several mechanisms for de novo EGFR-TKI resistance have been reported, and the concurrent strategy with cytotoxic agents might circumvent such resistance.
Although almost half of the patients experienced a grade 3 or greater hematological adverse event in this study, these events were predictable and manageable. At the time this study was planned, an AUC = 6 of carboplatin was utilized based on results of a study that had shown that a combination of pemetrexed 500 mg/m 2 plus carboplatin (AUC = 6), followed by pemetrexed maintenance therapy, had been generally tolerated in a Japanese population [24] . The incidence of hematological adverse events in this study was similar with those previously reported following carboplatin (AUC = 6) and pemetrexed treatment [25] . Additionally, interstitial lung diseases were not frequent in this study when compared with the reported incidence following gefitinib monotherapy [26, 27] , and these events were reversible. Thus, the combination of gefitinib and carboplatin/pemetrexed does not appear to have additive toxicity.
However, 41.5% of patients in the concurrent regimen group required dose reductions of carboplatin/pemetrexed. A lower incidence of adverse hematological events is preferred, as such, an AUC of 5 has been adopted in the NEJ009 study.
One limitation of this study is related to the nature of a phase II evaluation; specifically, this study was not designed to formally identify a difference in the efficacy and safety between the two regimens. Therefore, the findings obtained in this study should not be considered definitive.
In conclusion, this study demonstrated that both concurrent and sequentially alternating regimens with a combination of gefitinib and carboplatin/pemetrexed had promising efficacy with predictable toxicities for patients with NSCLC harboring EGFR mutations. The concurrent regimen was chosen as an experimental arm in an ongoing phase III NEJ009 study. The NEJ009 study will clarify whether this combinational strategy can be implemented into routine clinical practice. Supplementary Table S3 . 
SUPPLEMENTARY FIGURE LEGENDS
Supplementary Figure S1 . NEJ005/TCOG0902 study design Patients in the concurrent regimen group received concurrent gefitinib and carboplatin/pemetrexed (CP) in a 3-week cycle for up to six cycles, followed by concurrent gefitinib and pemetrexed (P) maintenance. Patients in the sequential alternating regimen group initially received 8 weeks of gefitinib (days 1 to 56) and then CP (day 57 and 79); this sequential treatment was repeated up to three times (CP was repeated for up to six cycles), followed by alternating maintenance.
Supplementary Figure S2 . Kaplan-Meier curve of progression-free survival according to type of common mutation (Del19 or L858R). There were no significant differences in PFS according to type of mutation.
Supplementary Figure S3 . Kaplan-Meier curve of overall survival according to type of common mutation. Patients with Del19 had relatively better OS than those with L858R. In the Del19 group, median OS was 41.9 months in the concurrent regimen group and 33.3 months in the sequential alternating regimen group (p = 0.028). 
Dose Modification
The National Cancer Institute Common Terminology Criteria for Adverse 
Supplementary Data 3
Treatment Delivery
In the concurrent regimen group, six patients discontinued induction treatment and did not proceed to maintenance treatment due to toxicities. The remaining 35 patients (85.4%) received maintenance treatment after completion of the induction treatment (gefitinib plus pemetrexed, n = 30; gefitinib alone, n = 5) ( Figure 1) . The median number of cycles of pemetrexed maintenance was 13 (range, 1 to 49). The median duration of gefitinib treatment (excluding interruption) was 17.3 months (range, 2.9 to 49.5 months) for the entire treatment period.
In the sequential alternating regimen group, 15 patients discontinued induction treatment and did not proceed to maintenance treatment (progression n = 6; toxicities, n = 8; withdraw, n = 1). The remaining 24 patients (61.5%) received maintenance treatment after induction (gefitinib plus pemetrexed, n = 17; gefitinib alone, n = 7) ( Figure 1 ). The median number of cycles of pemetrexed maintenance was 7 (range, 1 to 25). The median duration of gefitinib treatment (excluding interruption) was 11.4 months (range, 0.3 to 42.5 months) for the entire treatment period. Adverse events causing early discontinuation of the protocol treatment are shown in Supplementary Table S3 .
More patients in the concurrent regimen group required dose reductions of carboplatin/pemetrexed than did those in the sequential alternating regimen Eight patients in the concurrent regimen group and six patients in the sequential alternating regimen group did not have progression at the time of data cutoff. In addition, one patient and two patients started off-study treatment before confirmation of progression in the groups.
Upon confirmation of disease progression, 57 of the 63 patients (90.5%, 29 patients in the concurrent and 28 patients in the sequential alternating regimen group) received subsequent treatment excluding palliative radiotherapy and best supportive care. Among them, 15
(46.9%) and 19 patients (61.3%) had protocol maintenance treatment beyond progression in the concurrent and sequential alternating regimen group, respectively, whereas 14 (43.8%) and nine patients (29.0%) received other treatment. Subsequently, 19 (59.4%) and 22 patients (71.0%) received EGFR-TKI treatment (gefitinib and pemetrexed, gefitinib, or erlotinib) beyond progression. Supplementary Table S3 . Adverse events causing early discontinuation of the protocol treatment 
